In post-myocardial infarction patients with moderate CKD and increased high-sensitivity C-reactive protein concentrations, the inhibition of IL-1β with the monoclonal antibody canakinumab reduced major adverse cardiovascular events [353]. The gene discussed is IL1B; the disease is chronic kidney disease.